Healthcare
Zeo ScientifiX, Inc.(ZEOX)
Live Price
Offline$1.70
-3.95% today
1Y Change
-28.27%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +12.5%
- EPS Growth
- -16.2%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zeo ScientifiX, Inc. (ZEOX) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $1.70 and down 28.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +12.5%, EPS growth of -16.2%, a dividend yield of 0.0%. What stands out right now is revenue +12.5%, EPS -16.2%, free cash flow +48.9% with operating margin -90.2% and ROIC 1796.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZEOX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.5% vs +7.6% peer median
Operating Margin
Below sector median
-90.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 17, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +12.5% and EPS is at -16.2%, with operating margin around -90.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -9.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 17, 2026 | โ | +0.1% | +0.0% | -5.3% |
2026 Jan 29, 2026 | โ | +3.3% | -19.8% | -5.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZEOX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZEOX Max Drawdown
-47.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZEOX and SPY.
Company Overview
Zeo ScientifiX, Inc.
Other OTC
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company's lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body's natural ability to decrease cellular inflammation and promote tissue healing. In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROW X, a professional-grade formula that delivers a concentrated dose of topical exosomes that help support follicular function; ZEO GROW BOOST; and EXO FOLLICLE FUEL. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is headquartered in Davie, Florida.
- Leadership
- Ian T. Bothwell
- IPO Date
- Mar 1, 2016
- Employees
- 20
- Street Address
- 3321 College Avenue
- Mailing
- Davie, FL, 33314
- Region
- Davie, FL, US
- Reporting Currency
- USD
- Investor Line
- 888 963 7881
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.8
- Price/Book
- โ
Growth
- Revenue
- +12.5%
- EPS
- -16.2%
- Free Cash Flow
- +48.9%
Profitability
- Gross Margin
- 81.6%
- Operating Margin
- -90.2%
- Net Margin
- -92.3%
- ROE
- 329.9%
- ROIC
- 1796.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.